Nuventra posted a video "Regulatory Pathways for Drugs, Devices, & Combination Products" on VIMEO

This webinar covers regulatory pathways for drugs, devices, and combination products. Nuventra's Dr. Lamson provides his insights on the 505(b)(2) pathway for new drugs while Gilero's Ms. Benokraitis discusses a variety of regulatory pathways for devices, including 510(k), Premarket Approval (PMA), and De Novo. The presentation concludes with a discussion of how these various regulatory pathways intersect for drug-device combination products.At the end of this webinar, attendees should have a better understanding of:1. How to use the 505(b)(2) pathway to streamline drug development effectively2. Which device regulatory pathway is appropriate for your standalone device or combination product3. The interplay of drug and device pathways for developing combination products